Kumiko Yoshida

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Tomohiro Yoshida, Fumihiko Akahoshi, Hiroshi Sakashita et al. · Bioorganic & Medicinal Chemistry · 2012 · 148 citations · Full text

Biochemistry, Medicine, Rational Drug Design +7

Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents

Takahiro Oguma, Keiko Nakayama, Chiaki Kuriyama et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 69 citations

Detection of in vivo genotoxicity of haloalkanes and haloalkenes carcinogenic to rodents by the alkaline single cell gel electrophoresis (comet) assay in multiple mouse organs

Yū F Sasaki, Ayako Saga, Makiko Akasaka et al. · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · 1998 · 56 citations

Multiple Mouse Organs, Medicine, Photocarcinogenesis +9

Formation of toxic metabolites from thiabendazole and other thiazoles in mice. Identification of thioamides as ring cleavage products.

Tetsuya Mizutani, Kumiko Yoshida, Souichirou Kawazoe · Drug Metabolism and Disposition · 1994 · 53 citations

A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations

Sayaka Fukuda-Tsuru, Jun Anabuki, Yuji Abe et al. · European Journal of Pharmacology · 2012 · 47 citations

Metabolic Syndrome, Diabetes Management, Biochemistry +9